DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
▼ + stars: | 2024-11-06 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance. The Danish pharmaceutical giant said that its net profit in the third quarter hit 27.3 billion Danish kroner ($3.92 billion), above an LSEG aggregate estimate of 26.95 billion Danish kroner. EBIT — earnings before tax and income — came to 33.8 billion Danish kroner, also just above the LSEG forecast of 33.51 billion Danish kroner. The guidance reflected the company's expectations for sales growth in North America and internationally, which is largely driven by volume growth of treatments based on Glucagon-like peptide-1 (GLP-1), Novo Nordisk said. Novo Nordisk added that it was investing in capacity both internally and externally to increase supply in the short- and long-term.

Persons: —, — CNBC's Annika Kim Constantino Organizations: Novo Nordisk, Wednesday, Novo, Nordisk, U.S . Food, Drug Administration Locations: Danish, North America, Novo, U.S

☆ Here are Tuesday's biggest analyst calls: Apple, Microsoft, Palantir, Eli Lilly, Broadcom, Krispy Kreme, Live Nation & more
▼ + stars: | 2024-11-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Morgan Stanley reiterates Live Nation as overweight Morgan Stanley raised its price target on the stock to $140 per share from $120. Bank of America reiterates Apple as buy Bank of America says it sees "limited" impact to Apple earnings regardless of the Presidential outcome. Bank of America reiterates Palantir as buy The firm says Palantir is an AI "juggernaut" following earnings on Monday. Bank of America reiterates Arista Networks as buy Bank of America says it sees share gains ahead for the networking equipment company. Morgan Stanley reinstates Krispy Kreme as equal weight Morgan Stanley says Krispy Kreme has a balanced risk/reward right now.

Persons: Morgan Stanley, it's bullish, Eli Lilly, Palantir, Bernstein, Eaton, Deutsche, there's, Jefferies, Rick Dreiling, MTZ, Morgan Stanley reinstates Krispy, Krispy Kreme Organizations: Bank of America, Boeing, JPMorgan, RBC, Microsoft, " Bank of America, Broadcom, Apple, Republicans, Arista Networks, Arista, Meta, Deutsche Bank, eBay, Barclays, Energy, Infrastructure, Communications, Resources, IDA Locations: San Antonio, Redmond , WA

☆ Stocks making the biggest moves premarket: Trump Media, Talen, Nvidia, Apple and more
▼ + stars: | 2024-11-04 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

The drug is classified as a GLP-1, which could put the company in competition with Novo Nordisk and Eli Lilly. Berkshire Hathaway – Shares were marginally lower after Warren Buffett's conglomerate revealed that operating earnings totaled $10.1 billion in the third quarter . Berkshire Hathaway shares were marginally lower after operating earnings totaled $10.1 billion in the third quarter. Trump Media & Technology Group – Shares of former President Donald Trump's media company pulled back more than 3% ahead of the U.S. election on Tuesday. Shares of Intel were more than 1% lower, while Dow Inc. shares were off 0.6%.

Persons: Talen, Eli Lilly, Berkshire Hathaway, Warren Buffett's, Warren Buffett's Berkshire Hathaway, Peter Stern, Donald Trump's, Roblox, Morgan Stanley, Jefferies, Sherwin, Williams, William, CNBC's Hakyung Kim, Brian Evans, Sarah Min, Lisa Kailai Han, Spencer Kimball, Tanaya Macheel, Michelle Fox Theobald Organizations: Energy, Federal Energy Regulatory Commission, Susquehanna, Constellation, Therapeutics, Novo Nordisk, Apple, Berkshire, –, Bank of America, Trump Media & Technology, Nvidia, Dow Jones, Intel, Dow Inc

☆ Cramer raves about Salesforce's star-powered plan to raise awareness of its new AI agents
▼ + stars: | 2024-11-04 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. In his Sunday column, meanwhile, Jim Cramer looked at 11 earnings surprises , including a feeling that both presidential candidates would support solar. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, There's, that's, there's, Eli Lilly, Lilly, Stanley Black, Decker, Nextracker, Jim, Salesforce, Evercore, Agentforce, he's, Saleforce's, Matthew McConaughey, Stocks, Sherwin, Berkshire Hathaway, Jim Cramer's, NVDA Organizations: CNBC, Fed, Devices, Nvidia, Intel, Dow, Therapeutics, Depot, ISI, Abercrombie, Fitch, Constellation Energy Locations: Friday's, Williams, Berkshire, Marriott

☆ 11 surprising things from this earnings season, including my favorite stock so far
▼ + stars: | 2024-11-03 | by ( Jim Cramer | ) www.cnbc.com time to read: +17 min

Horton makes the most sense as a Kamala Harris stock because of a promised $25,000 toward a first home. I don't know if either candidate can pull off huge tariffs (Trump) or a credit (Harris). Here are eleven surprising things about this earnings season that you can store up and pull out when the election is confirmed. The deficit will begin to hurt the stock market hard next year even if the economy continues to cool. Away from the hyperscalers, I like Marvell , where CEO Matt Murphy bought $1 million worth of stock in the open market.

Persons: beckons, Joe Biden, Biden, Donald Trump, D.R, Horton, Kamala Harris, Harris, let's, Let's, Trump, haven't, Myers, Abbvie, Eli Lilly, Anat Askenazi's, Abbott, neonatologists, Reckitt, Jim Hurst, Danaher, Jason Hollar, It's, Amgen, That's, Estee Lauder, Parker, Pat Gelsinger's, He's, Matt Murphy, Jim Cramer's, Jim Cramer, Jim, David Paul Morris Organizations: U.S, NBC News, White, Ford Motor, Trump, Costco, Volkswagen, Bankers, Banco Santander, Apple, Amazon, GE Vernova, U.S ., Treasury, Merck, NEC, FDA, CDC, NIH, GE Healthcare, Cardinal Health, NPC, Nvidia, Caterpillar, Linde, Devices, heaven's, Intel, Marvell, Micron, Arista, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: Europe, Germany, China, Portugal, Ireland, Italy, Greece, Spain, It's, Santander, —, Bristol, U.S, Taiwan, Eaton, Dover, Norwegian, Caribbean, San Francisco

☆ Eli Lilly's quarter was messy. What to do with the stock is more clear-cut
▼ + stars: | 2024-10-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

The report was messy, but it doesn't dim Eli Lilly's bright multiyear outlook, rendering the dip in the stock as a chance to buy. LLY .SPX 5Y mountain Eli Lilly's five-year stock performance compared with the S & P 500. Bottom line We're upgrading Eli Lilly to our buy-equivalent 1 rating and leaving our price target of $1,000 a share unchanged. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA in July, was not a major focus on the call.

Persons: Eli Lilly, Eli, Eli Lilly's, Jim Cramer, Jim, —, that's, David Ricks, Ricks, Semaglutide, Wegovy, Lilly, There's, Mounjaro, Trulicity, Verzenio, Jim Cramer's, Cristina Arias Organizations: Revenue, The Club, CNBC, JPMorgan, Novo Nordisk, Food, Novo Nordisk's, FDA, Zepbound, Biogen, Merck, Pfizer, Morphic, Company, Pharmaceutical Locations: Tuesday's, U.S, Novo, Eisai, FactSet, Zepbound, Alcobendas, Madrid, Spain

☆ We see two post-earnings declines as buys, while happy to see a Tuesday laggard stabilize
▼ + stars: | 2024-10-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Then there were selloffs in Club stocks Eli Lilly and Advanced Micro Devices after their earnings releases. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Lilly's, AMD's financials, Stanley Black, Decker, Estee Lauder, Jim Cramer's, Jim Organizations: CNBC, Dow, Caterpillar, Devices, Nasdaq, Microsoft, Starbucks, MGM Resorts, Linde, Merck, ConocoPhillips, Mastercard, Roblox, Myers, Jim Cramer's Charitable Locations: Bristol

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

☆ Weight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continues
▼ + stars: | 2024-10-29 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +6 min

The startup says care for GLP-1 patients has become its most popular front door for new customers. AdvertisementLast spring, diabetes startup Omada Health said it wanted to help employers manage patients taking a blockbuster new class of weight-loss drugs. Omada Health's metabolic health program has now become the entry point for most new employers considering contracts with Omada Health, Duffy said. Launched in 2011, Omada provides virtual care for diabetes, hypertension, musculoskeletal care, and diabetes prevention, alongside obesity, to employers, health plans, and even health systems. The firm said GLP-1 drugs for obesity account for about 10% of all pharmacy spending.

Persons: —, Duffy, Omada, haven't, buzzy, Willis Towers Watson Organizations: Service, Omada Health, Business, Nordisk's Ozempic Locations: WeightWatchers, GLP

☆ 14 earnings reports and major economic data will be the stock market movers this week
▼ + stars: | 2024-10-27 | by ( Zev Fima | ) www.cnbc.com time to read: +15 min

The Street is looking for Stanley Black & Decker sales of $3.8 billion in the third quarter and earnings per share (EPS) of $1.05. The Street is looking for Linde sales of $8.35 billion in the third quarter and EPS of $3.89. In addition to the headline results and forward guidance, overall organic sales growth and data center energy power demand will be focus items for investors. The Street is looking for sales of $94.47 billion in its fiscal fourth quarter and EPS of $1.55. The Street is looking for Coterra sales of $1.3 billion in the third quarter and EPS of 34 cents.

Persons: That's, It's, Stanley Black, Decker, we're, We're, Eli Lilly, Lilly, Amy Hood's, Brian Niccol, Wednesday's, Linde, it's, we'll, Phillips, Horton, Kraft Heinz, SIRI, Estee Lauder, BUD, Cardinal Health, Jim Cramer's, Jim Cramer, Jim, Stephanie Keith Organizations: Nasdaq, Dow, Fed, PCE, YouTube, Justice, AMD, GE Healthcare, Reality Labs, Microsoft, Management, Starbucks, U.S, Presidential, Linde, Apple Intelligence, Amazon, Services, Coterra Energy, WM, Cadence Design Systems, Labor, PayPal, BP, Pfizer, Royal Caribbean Cruises, JetBlue, HSBC, Devices, Grill, Electronic Arts, EA, Gross, Caterpillar, Brinker International, AFortive Corporation, Illinois Tool, Coinbase, eBay, EBAY, Booking Holdings, MGM Resorts, MGM, Bausch Health, LIN, Merck, ConocoPhillips, Mastercard, Altria, Cruise, Myers Squibb, Comcast, Mobileye, Cheniere Energy, Regeneron Pharmaceuticals, Anheuser, Busch InBev, Intel, United States Steel, Juniper Networks, Chevron, Exxon Mobil, Dominion Energy, Charter Communications, LyondellBasell Industries, Cardinal, Jim Cramer's Charitable, CNBC, New York Stock Exchange, Getty Locations: Eaton, Corning, Illinois, Bristol, New York City

☆ How to dance the earnings two-step: Recognize initial stock distortions and then act
▼ + stars: | 2024-10-27 | by ( Jim Cramer | ) www.cnbc.com time to read: +18 min

For all we know, the yield curve may simply be going through the birthing of an un-inverted yield curve. GOOGL YTD mountain Alphabet YTD Search used to be so simple. META YTD mountain Meta Platforms YTD Meta Platforms has run big ahead of the quarter. AMZN YTD mountain Amazon YTD Let's get to the two toughest of the week, Amazon and Apple. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: let's, Eli Lilly, nonfarm payrolls, Carl Quintanilla, batty, Jeff Marks, Waymo, Elon Musk, Donald Trump, Kamala Harris, Department's, Mark Zuckerberg, Jensen Huang, Marc Benioff, Trump, Warren Buffett, Jim Cramer's, Jim Cramer, Jim Organizations: CNBC, Microsoft, Apple, Treasury, Federal Reserve, charlatans, Honeywell, Twitter, Club, Gemini, YouTube, Google, Donner Party of cannibalization, AMD, Nvidia, Intel, Merck, Pfizer, Tech Titans, Meta, Amazon Web Services Locations: Wall, cyclicals, California, Philly

☆ Cramer’s week ahead: Earnings from Alphabet, Meta, Apple, Microsoft and Amazon
▼ + stars: | 2024-10-25 | by ( Kristian Burt | In | ) www.cnbc.com time to read: +4 min

With massive corporations including Alphabet , Meta , Apple , Microsoft and Amazon set to report earnings next week, CNBC's Jim Cramer on Friday urged investors to keep a level head. "Just please remember, the first move's been the wrong move almost half the time since this earnings season began. Monday starts off the week with earnings from Ford . Tuesday brings McDonald's earnings report, and Cramer said to expect "a full airing of the e-coli situation," but that it is too early to tell how much damage it will do to the fast food chain. The monster week for earnings will continue into Thursday, as both Apple and Amazon will report after the bell.

Persons: CNBC's Jim Cramer, Cramer, Chipotle, Brian Niccol's, Eli Lilly, Meta, Chevron's, Hess, Exxon doesn't Organizations: Apple, Microsoft, Federal Reserve, Ford, Disease Control, Prevention, Royal, PayPal, Caterpillar, Meta, Merck, Bristol, Oil titans Chevron, Exxon, Chevron Locations: Gulf of Mexico, Myers

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia. Another study, published in August, found that semaglutide appeared to cut the risk of dementia in people with Type 2 diabetes. Type 2 diabetes is a risk factor for dementia and Alzheimer’s. The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Persons: —, semaglutide, ”, Stephen Salloway, ” Salloway, Rong Xu, liraglutide, Xu, ” Xu, they’re, Salloway, they’ve, Donna Wilcock, there’s, ” Wilcock, Dr, Alberto Espay, Espay, What’s, “, ” Espay Organizations: Alzheimer’s Association, Conference, Novo Nordisk, Warren Alpert Medical, Brown University, Center, Artificial Intelligence, Case Western Reserve University School of Medicine, Drug Administration, ”, Alzheimer’s, Indiana University School of Medicine, University of Cincinnati College of Medicine Locations: Novo, Rhode Island, Ohio

☆ Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
▼ + stars: | 2024-10-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Novo Nordisk 's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Alzheimer's disease is often diagnosed in the mild dementia stage, when a person has significant trouble with memory and thinking. But the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. by 2050. Novo Nordisk, which did not fund the new Case Western study, is also examining semaglutide in a late-stage study on Alzheimer's patients. In the liraglutide research, data from a midstage trial found that the drug may slow the progression of Alzheimer's disease by protecting patients' brains.

Persons: Semaglutide, Dr, Rong Xu, it's, Xu, Eli Lilly, Wegovy, Eli Lilly's Organizations: Novo Nordisk, Alzheimer's Association, Case Western Reserve University, CNBC, Nordisk, Case, National Institutes of Health, GLP Locations: U.S, Novo

☆ Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
▼ + stars: | 2024-10-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. In a statement, the agency said it is reviewing the petition and will respond directly to Novo Nordisk. The active ingredient in Wegovy and Ozempic, semaglutide, has been in intermittent shortages over the past two years. Like Novo Nordisk, Eli Lilly has sued several weight loss clinics, medical spas and compounding pharmacies across the U.S. over the past year.

Persons: Wegovy, Danish drugmaker, semaglutide, Eli Lilly, Eli Lilly's, compounders Organizations: Novo Nordisk, Tuesday, Food and Drug Administration, FDA, Nordisk Locations: Novo, Danish, U.S

☆ Convenient No More: Why CVS, Walgreens, 7-11 Are in Trouble
▼ + stars: | 2024-10-21 | by ( Emily Stewart | ) www.businessinsider.com time to read: +14 min

What's more, many pharmacies serve as a convenient destination for all sorts of essentials, from aspirin to mascara. Big chains like Walgreens and CVS make their money in two main ways: selling prescriptions in the back of their stores and selling everyday goods out front. As Walgreens and CVS stores have proliferated over the past decade or so, many of their locations are basically right on top of each other. On the other end of the business, pharmacies are expensive to run. In the current landscape of commoditized pharmacies, there's no such thing as personalized service.

Persons: What's, Elizabeth Anderson, Neil Saunders, nilly, they've, Douglas Hoey, Jason Goldberg, Waits, Duane Reade, Brian Tanquilut, I've, Goldberg, Saunders, I'm, Nick Fabrizio, Steven Anderson, Fabrizio, Emily Stewart Organizations: Walgreens, CVS, Rite, Evercore ISI, Walmart, National Community Pharmacists Association, Express, Groupe, Jefferies, MTV, Cornell University, National Association of Chain Drug, Business Locations: mascara

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
▼ + stars: | 2024-10-16 | by ( Karen Gilchrist | Karen Gilchrist Is A Reporter For Cnbc.Com. | ) www.nbcnews.com time to read: +4 min

LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The weight-loss treatment firm and creator of Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain’s significant health challenges — including obesity. Within that, the five-year trial, conducted in collaboration with Health Innovation Manchester, will also explore how weight-loss drugs impact “participants’ employment status and sick days from work,” the company said in a news release. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, ”, Rachel Batterham, Wes Streeting, Streeting, “ It’s, ” Streeting, Peter Verdault, “, Dr, Dolly van Tulleken, Eli Lilly’s Organizations: LONDON, U.K, of Health, Social, Department for Science, Innovation, Technology, Labour government’s, Investment, National Health Services, Health Innovation, International Medical, British Health, Social Care, Covid, NHS can’t, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly, Labs Locations: Lilly, British, Europe

☆ Embattled Abbott Labs comes through with a strong quarter, buyback announcement
▼ + stars: | 2024-10-16 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

Organic sales, which exclude Covid testing, were up 8.2% from the year-ago period. Bottom line In its third quarter, Abbott Labs demonstrated why we wanted to stick with the stock in the face of legal battles that emerged earlier this year and spooked investors. "There's just a lot to like with the Abbott quarter." As Abbott's organic sales growth continues to shine, the market will realize both concerns are overblown. The company reiterated its full-year organic sales growth outlook of 9.5% to 10%.

Persons: ABT, Abbott, Jim Cramer, Dexcom, Robert Ford, Ford, Lingo, —, it's, Edwards, Jim Cramer's, Jim, Ethan Miller Organizations: Abbott Laboratories, Revenue, Abbott Labs, NEC, Abbott, Ford, and Drug Administration, Centers for Disease Control, National Institutes of Health, CNBC, Las Vegas Convention, Getty Locations: U.S, Missouri, Las Vegas , Nevada

Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Broadcom: Of course, we love the company's AI business — both its custom silicon solutions for companies such as Alphabet and its networking chips that help stitch data centers together. Stanley Black & Decker: Jim said that this stock is the "most significant beneficiary" from lower rates in the entire portfolio. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, there's, Lisa Su, Wells, Salesforce, CrowdStrike, it's, we've, Walt Disney, —, Eaton, we're, Kamala Harris, Harris, Jim's, Linde, Eli Lilly, Lilly isn't, That's, Morgan Stanley, Goldman Sachs, D.A, Satya Nadella's, Palo, cybersecurity, Brian Niccol, We're, Stanley Black, Decker, TJX, Charlie Scharf, Wells Fargo's, Jim Cramer, Angela Weiss Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple Intelligence, Abbott Laboratories, Devices, AMD, Nvidia, Broadcom, Apple, Federal Reserve, Costco Wholesale, Costco, Coterra, DuPont, Disney, ESPN, GE Healthcare, Democratic, Biden, Honeywell, Linde, Adobe, Microsoft, Davidson, Palo Alto Networks, Constellation Brands, Modelo, Corona, TJX, Jim Cramer's Charitable, New York Stock Exchange, AFP, Getty Locations: Wells Fargo, BlackRock, Dover, Eaton, China, U.S, Chipotle, New York City

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
▼ + stars: | 2024-10-15 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. Speaking to CNBC last week, Citi pharmaceuticals analyst Peter Verdault said the body of evidence to support increased use of weight-loss drugs "keeps coming." The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, Rachel Batterham, Lilly, Wes Streeting, Covid, Streeting, Peter Verdault, Dolly van Tulleken, Eli Lilly's Organizations: LONDON, U.K, Department of Health, Social, Department for Science, Innovation, Technology, Labour government's, Investment, National Health Services, Health Innovation, International Medical, Social Care, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly Locations: Brooklyn, New York, Europe

☆ Here's an earnings homework checklist so you can be ready when your companies report
▼ + stars: | 2024-10-15 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

Wells Fargo on Friday was the first portfolio name to report third-quarter results, which have been greeted enthusiastically on Wall Street. Morgan Stanley and Abbott Laboratories — both Club names as well — report earnings before Wednesday's opening bell. Revenue and earnings estimates can be found on stock ticker pages on any number of free financial websites and through brokerage account providers. Portfolio management is a must. After considering these factors, be sure to then take a higher-level portfolio management view of your investments.

Persons: Wells, Morgan Stanley, Abbott Laboratories —, Jim Cramer's, —, Eli Lilly, writeups, Stanley Black, Decker, Jim, Jim Cramer, Andrew Kelly Organizations: Abbott Laboratories, Abbott Labs, Microsoft, TJX, Palo Alto Networks, Club, Nvidia, Devices, Taiwan Semiconductor Management Company, Jim Cramer's Charitable, CNBC, Flag, New York Stock Exchange Locations: Wells Fargo, U.S

The FDA’s announcement on Oct. 2 declaring the shortage over meant that compounding pharmacists had to stop filling tirzepatide prescriptions. Simone Williams, 50, of Spartanburg, S.C was prescribed compounded tirzepatide in June 2023 after her Mounjaro savings card expired. Williams began taking compounded tirzepatide for weight loss last year after her Mounjaro savings card expired. Tirzepatide was on the FDA’s drug shortage list for nearly two years. ‘Peace of mind’Meanwhile, patients and compounding pharmacists are celebrating the FDA decision to allow tirzepatide compounding to continue.

Persons: Lilly’s, Mounjaro, Zepbound, semaglutide, Wegovy, drugmakers, tirzepatide, “, Simone Williams, S.C, Simone Williams Simone Williams, Williams, ” Williams, she’s, I’m, ”, Lilly, Michael Ganio, Ganio, Dr, Christopher McGowan, ” McGowan, ” Lilly, Jared Shapiro, ’ ” Shapiro, Elizabeth Kenly, ” Kenly, Kenly Organizations: Drug Administration, FDA, Association, American Society of Health, System, Outsourcing, Alliance, Pharmacy, APC Locations: Spartanburg, Spartanburg , South Carolina, U.S, Cary , North Carolina, Graham , North Carolina

☆ Jefferies says buy this little-known injectable drug delivery maker with more than 30% upside
▼ + stars: | 2024-10-14 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

It's time to buy shares of this under-the-radar injectable delivery and beauty packaging maker with more than 30% upside potential, according to Jefferies. Analyst Daniel Rizzo upgraded shares of Aptargroup to a buy rating, saying that new pharmaceutical delivery products should drive 10% sales growth on a compound annual basis through 2027. Along with the upgrade, Rizzo boosted his price target by 39% to $215 a share, representing 33% upside from Friday's close. The firm also forecasts that the company can drive 7% to 11% pharmaceuticals sales growth over the next 10 years, given that 80% of its delivery systems are protected by intellectual property tools such as patents. "The stock is up ~30% YTD ... but as new products help earnings accelerate, we expect multiple expansion to help support another ~30% increase."

Persons: Daniel Rizzo, Rizzo Organizations: Jefferies, OTC Narcan, pharma Locations: Aptargroup, U.S

☆ Here are Monday's biggest analyst calls: Nvidia, Broadcom, Apple, Tesla, Flutter, Caterpillar, Alphabet & more
▼ + stars: | 2024-10-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are the biggest calls on Wall Street on Monday: TD Cowen reiterates Nvidia as buy TD said Nvidia remains a top pick at the firm. Goldman Sachs upgrades Ibotta to buy from neutral Goldman Sachs reiterates Alphabet as buy Goldman lowered its price target on the stock to $208 per share from $217 citing a slew of headwinds for Alphabet. Wells Fargo upgrades Flutter to overweight from equal weight Wells says investors should buy the dip in shares of the gambling company. Goldman Sachs downgrades AutoZone to sell from buy Goldman downgraded the auto parts retailer due to "muted growth." Goldman Sachs upgrades Ibotta to buy from neutral Goldman says it likes the growth opportunity for the mobile tech company.

Persons: TD Cowen, Mizuho, Goldman Sachs, Goldman, Wells, Truist, Morgan Stanley, Caterpillar, Piper Sandler, Tesla, Piper, wouldn't, it's, Baird, KeyCorp, Jefferies, it's bullish, Stock, GOOS, AppLovin, Oppenheimer Organizations: Nvidia, NVIDIA, Away Tech, Mizuho, AMD, Broadcom, UBS, Partners, Surgery Partners, Apple, VF Corp, Vans, UW, Walmart Locations: Wells Fargo, China

☆ Ozempic-fueled slimming is blowing up the wedding dress industry
▼ + stars: | 2024-10-11 | by ( Allison Morrow | ) edition.cnn.com time to read: +6 min

New York CNN —Price distortions and dysfunction are nothing new in the $73 billion wedding industry. For better or worse, many brides are using the drugs ahead of their big day, lured in by the promise of rapid weight loss. The right fitThe ideal time to buy a wedding dress is eight to 10 months before the event, according to wedding planning site the Knot, and some planners recommend buying a full year in advance in case of shipping delays. “Usually, the dress was ordered somewhere in the middle of those 50 pounds.”It’s hard to overstate how such drastic weight loss can complicate a wedding dress’ fit. “Weight loss has always been a top of priority.

Persons: CNN Business ’, Tami Luhby, Susan Ruddie, Dresser, Spring, That’s, they’re, ”, Myrna Lundberg, “, Lundberg, ” Lundberg, “ It’s, — it’s, you’re Organizations: CNN Business, New York CNN, FDA, Drug Administration, Bureau of Labor Statistics, CNN Locations: New York, China, Suez, United States

Search resuls for: "GLP"

25 mentions found